-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Incannex Healthcare Limited (NASDAQ:IXHL) Short Interest Update
Incannex Healthcare Limited (NASDAQ:IXHL) Short Interest Update
Incannex Healthcare Limited (NASDAQ:IXHL – Get Rating) was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 11,000 shares, a decrease of 24.7% from the December 31st total of 14,600 shares. Based on an average trading volume of 6,800 shares, the days-to-cover ratio is currently 1.6 days.
Incannex Healthcare Stock Down 0.9 %
Incannex Healthcare stock opened at $3.41 on Monday. Incannex Healthcare has a twelve month low of $2.60 and a twelve month high of $90.00. The stock's fifty day simple moving average is $3.34 and its 200-day simple moving average is $3.98.
Get Incannex Healthcare alerts:Institutional Trading of Incannex Healthcare
Large investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in shares of Incannex Healthcare during the first quarter worth $378,000. FNY Investment Advisers LLC acquired a new position in shares of Incannex Healthcare during the third quarter worth $69,000. Finally, UBS Group AG acquired a new position in shares of Incannex Healthcare during the first quarter worth $25,000. Hedge funds and other institutional investors own 0.07% of the company's stock.
About Incannex Healthcare
(Get Rating)Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. It offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. The company also develops IHL-42X, which has completed Phase IIa clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis.
Featured Articles
- Get a free copy of the StockNews.com research report on Incannex Healthcare (IXHL)
- Is Seagate Technology Signaling the End of its Normalization?
- eHealth Stock Rises from the Ashes. Time to Get In?
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
Receive News & Ratings for Incannex Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incannex Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
Incannex Healthcare Limited (NASDAQ:IXHL – Get Rating) was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 11,000 shares, a decrease of 24.7% from the December 31st total of 14,600 shares. Based on an average trading volume of 6,800 shares, the days-to-cover ratio is currently 1.6 days.
Incannex Healthcare Limited(纳斯达克股票代码:IXHL — 获取评级)是1月份空头利率大幅下降的目标。截至1月15日,空头利率共计11,000股,较12月31日的14,600股总额下降了24.7%。根据6,800股的平均交易量,目前的天数与覆盖率为1.6天。
Incannex Healthcare Stock Down 0.9 %
Incannex 医疗保健股价下跌0.9%
Incannex Healthcare stock opened at $3.41 on Monday. Incannex Healthcare has a twelve month low of $2.60 and a twelve month high of $90.00. The stock's fifty day simple moving average is $3.34 and its 200-day simple moving average is $3.98.
Incannex Healthcare股票周一开盘价为3.41美元Incannex Healthcare创下十二个月低点2.60美元,十二个月高点为90.00美元。该股的五十天简单移动平均线为3.34美元,其200天简单移动平均线为3.98美元。
Institutional Trading of Incannex Healthcare
Incannex 医疗保健的机构交易
Large investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in shares of Incannex Healthcare during the first quarter worth $378,000. FNY Investment Advisers LLC acquired a new position in shares of Incannex Healthcare during the third quarter worth $69,000. Finally, UBS Group AG acquired a new position in shares of Incannex Healthcare during the first quarter worth $25,000. Hedge funds and other institutional investors own 0.07% of the company's stock.
大型投资者最近修改了该股的持有量。Jane Street Group LLC在第一季度收购了价值37.8万美元的Incannex Healthcare股票的新头寸。FNY Investment Advisors LLC在第三季度收购了价值69,000美元的Incannex Healthcare股票的新头寸。最后,瑞银集团股份公司在第一季度收购了价值25,000美元的Incannex Healthcare股票的新头寸。对冲基金和其他机构投资者拥有该公司0.07%的股票。
About Incannex Healthcare
关于 Incannex 医疗保健
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. It offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. The company also develops IHL-42X, which has completed Phase IIa clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis.
Incannex Healthcare Limited在澳大利亚从事药用大麻素和迷幻药物和疗法的研究、开发和销售。它提供超纯四氢大麻酚apirx-1801;apirx-1802,超纯CBD;apirx-1803,超纯大麻酚。该公司还开发了 IHL-42X,它已经完成了阻塞性睡眠呼吸暂停的 IIa 期临床试验;psi-Gad 正在进行广泛性焦虑症 IIa 期临床试验;medChew Dronabinol,已完成化疗恶心和呕吐 IIa 期临床试验;apirx-1601,已完成白癜风 IIa 期临床试验;apirx-1601,已完成白癜风的 iiA 期临床试验;apirx-1601;apirx-1601,已完成白癜风的 iiA 期临床试验;apirx-1601 Iirx-1602 已完成银屑病 IIa 期临床试验;以及已完成 IIa 期临床试验的 apirx-1603特应性皮炎的临床试验。
Featured Articles
精选文章
- Get a free copy of the StockNews.com research report on Incannex Healthcare (IXHL)
- Is Seagate Technology Signaling the End of its Normalization?
- eHealth Stock Rises from the Ashes. Time to Get In?
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
- 免费获取 StockNews.com 关于 Incannex Healthcare (IXHL) 的研究报告的副本
- 希捷科技是否标志着其正常化的终结?
- eHealth 股票从灰烬中崛起。是时候进去了吗?
- Yext A.I. 搜索平台能否推动2023年的增长?
- Cassava Sciences 股票被低估了 124 美元的目标价?
- Constellation Brands:消费者在向下交易铁路饮料吗?
Receive News & Ratings for Incannex Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incannex Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
接收Incannex医疗日报的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Incannex Healthcare及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧